Alendronate
From Proteopedia
| Line 15: | Line 15: | ||
== Structure and General Function == | == Structure and General Function == | ||
[[Image:Alendronate.gif]]<ref>Image from: http://pharmacy-and-drugs.com</ref> | [[Image:Alendronate.gif]]<ref>Image from: http://pharmacy-and-drugs.com</ref> | ||
| - | Alendronate is an aminobisphosphonate with a nonhydrolyzable P-C-P. Alendronate generally affects the | + | |
| + | |||
| + | Alendronate is an aminobisphosphonate with a nonhydrolyzable P-C-P. Alendronate generally affects the activity of osteoclasts in bone. Osteoclasts are responsible for breaking down bone and also for bone resorption (losing bone substance). <ref>http://www.medterms.com/script/main/art.asp?articlekey=11794</ref> When alendronate is present, bone resorption is inhibited and bone breakdown is diminished. | ||
| Line 24: | Line 26: | ||
=== Protein-Tyrosine-Phosphatases (PTP) === | === Protein-Tyrosine-Phosphatases (PTP) === | ||
| - | Protein-Tyrosine-Phosphatses (PTPs) are reported to have an effect on osteoclast formation and Initial reports indicated that alendronate inhibited several types of PTPs, though specific mechanisms are not known. The data does suggest that alendronate works as an antagonist, which means that, when bound, the alendronate does not elicit a response from the protein but rather disallows the binding of an agonist which would cause a change (likely activating) in the protein.<ref>http://www.drugbank.ca/drugs/DB00630</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/8610169</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/9310349</ref> A | + | Protein-Tyrosine-Phosphatses (PTPs) are reported to have an effect on osteoclast formation and function.<ref> |
| + | <scene name='Sandbox_59/Ptpre/1'>TextToBeDisplayed</scene></ref> Initial reports indicated that alendronate inhibited several types of PTPs, though specific mechanisms are not known. The data does suggest that alendronate works as an antagonist, which means that, when bound, the alendronate does not elicit a response from the protein but rather disallows the binding of an agonist which would cause a change (likely activating) in the protein.<ref>http://www.drugbank.ca/drugs/DB00630</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/8610169</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/9310349</ref> A | ||
<scene name='Sandbox_59/Ptpre/1'>PTP example</scene> is given, so the binding site can be seen. | <scene name='Sandbox_59/Ptpre/1'>PTP example</scene> is given, so the binding site can be seen. | ||
=== Farnesyl Pyrophosphate Synthase (FPPS) === | === Farnesyl Pyrophosphate Synthase (FPPS) === | ||
<Structure load='2f92' size='450' frame='true' align='right' caption='Shown: The asymmetric subunit of FPPS, not the assumed biological molecule.' scene='Insert optional scene name here' /> | <Structure load='2f92' size='450' frame='true' align='right' caption='Shown: The asymmetric subunit of FPPS, not the assumed biological molecule.' scene='Insert optional scene name here' /> | ||
| - | |||
<scene name='Sandbox_59/Fpps/2'>FPPS</scene> is considered the main target protein of aminobisphosphonates (including alendronate). | <scene name='Sandbox_59/Fpps/2'>FPPS</scene> is considered the main target protein of aminobisphosphonates (including alendronate). | ||
| Line 41: | Line 43: | ||
<scene name='Sandbox_59/Fpps_bound_phosphate/2'>FPPS bound phosphate</scene> | <scene name='Sandbox_59/Fpps_bound_phosphate/2'>FPPS bound phosphate</scene> | ||
| - | <scene name='Sandbox_59/Fpps_hydrophobic/1'>hydrphobic FPPS</scene> | ||
Revision as of 10:02, 11 March 2011
| Please do NOT make changes to this Sandbox. Sandboxes 30-60 are reserved for use by Biochemistry 410 & 412 at Messiah College taught by Dr. Hannah Tims during Fall 2012 and Spring 2013. |
Contents |
Alendronate (Fosamax®)
Alendronate is commonly known for its use in treatment and prevention of osteoporosis in postmenopausal women and men, but is also used to treat Paget's disease (disease that results in deformed and enlarged bones).[1] Alendronate belongs to the class of nitrogen-containing bisphosphonates, which are inorganic pyrophosphate analogues.
History of Bisphosphonates
Bisphosphonates were first synthesized in Germany in 1865, but were not studied biologically until 1968. In the interim time, they were used in the textile and fertilizer industries due to their apparent inhibitory effect on calcium carbonate. However, in 1968, a group in Switzerland found inorganic pyrophosphates in urine and plasma. In vitro testing of these molecules revealed that they inhibited calcium phosphate precipitation and dissolution, but were destroyed in vivo by phosphatases. These results led to the discovery of bisphosphonates, as they reacted in the prescribed manner.[2]
Sodium alendronate was first marketed in 1994 as Fosamax® by Merck pharmaceutical. In 2008, Merck lost their U.S. patent on alendronate, allowing Barr Pharmaceuticals and Teva Pharmaceuticals USA to begin marketing generic forms of sodium alendronate. Other brand names for the drug include Fosamax+D®, Adronat, Alendros, Arendal, and Onclast.[3]
Structure and General Function
Alendronate is an aminobisphosphonate with a nonhydrolyzable P-C-P. Alendronate generally affects the activity of osteoclasts in bone. Osteoclasts are responsible for breaking down bone and also for bone resorption (losing bone substance). [5] When alendronate is present, bone resorption is inhibited and bone breakdown is diminished.
Target Proteins and Bone
Alendronate not only targets several proteins, but also directly binds to a bone mineral (hydroxyapatite), which causes the inhibition of bone resorption. The mechanism for this has not been elucidated.[6][7]
Protein-Tyrosine-Phosphatases (PTP)
Protein-Tyrosine-Phosphatses (PTPs) are reported to have an effect on osteoclast formation and function.[8] Initial reports indicated that alendronate inhibited several types of PTPs, though specific mechanisms are not known. The data does suggest that alendronate works as an antagonist, which means that, when bound, the alendronate does not elicit a response from the protein but rather disallows the binding of an agonist which would cause a change (likely activating) in the protein.[9][10][11] A is given, so the binding site can be seen.
Farnesyl Pyrophosphate Synthase (FPPS)
|
is considered the main target protein of aminobisphosphonates (including alendronate).
FPPS Natural Substrates
Isopentenyl pyrophosphate (IPP) actually binds to and stabilizes the alendronate-FPPS complex, rather than competing with the inhibitor.
Side affects of Drug
References
- ↑ http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000018/
- ↑ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC138713/?tool=pmcentrez
- ↑ http://www.drugbank.ca/drugs/DB00630
- ↑ Image from: http://pharmacy-and-drugs.com
- ↑ http://www.medterms.com/script/main/art.asp?articlekey=11794
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/20209564
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/16046206
- ↑
- ↑ http://www.drugbank.ca/drugs/DB00630
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/8610169
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/9310349
- ↑ Image from: http://reference.findtarget.com
